INTERMEDIATE TERM BIOCHEMICAL-FREE PROGRESSION AND LOCAL CONTROL FOLLOWING 125 IODINE BRACHYTHERAPY FOR PROSTATE CANCER
Authors:
- 1 March 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 173 (3) , 803-807
Abstract
We determined the 10-year biochemical and local control results for 125I prostate brachytherapy in men followed a minimum of 4 years. A total of 279 men with T1–T2 prostate cancer with a minimum followup of 4 years were implanted with 125I from 1990 to 1998 using the real-time technique. Patients were treated with the implant alone (215 or 72.5%) or with the implant and 6 months of hormone therapy (64 or 27.6%). Of the men 185 (66.3%) agreed to ultrasound guided biopsy (6 to 12 cores) a minimum of 2 years after implantation. All patients with increasing prostate specific antigen (PSA), evidence of local recurrence or a prior positive biopsy underwent repeat biopsy yearly until biopsy became negative or there was clear evidence of biochemical (PSA) progression. The radiation dose delivered to 90% of the gland (D90) was determined 30 days after implantation by computerized tomography based dosimetry. Biochemical failure was defined as 3 consecutive PSA increases. Survival curves were calculated by the Kaplan-Meier method. Cross tabulations were tested by Pearson chi-square analysis. The effect of multiple variables was tested by the log rank test (Cox regression). Median patient age was 67 years (range 42 to 82) and median followup was 6 years (range 4 to 12). Of the patients 49 (17.6%) experienced failure, for a 10-year freedom from failure (FFF) rate of 78%. Univariate analysis for 10-year FFF demonstrated that initial PSA (p = 0.001), stage (p = 0.002), risk group (p 90 (p 90 (p 90 of at least 140 Gy had a positive biopsy rate of 4.8% compared to 20.5% in those with a lower dose (p 125I brachytherapy. The delivered radiation dose and risk category are important predictors of success. Patients receiving a dose of at least 140 Gy have a 90% chance of biochemical FFF and a 95.2% likelihood of local control.Keywords
This publication has 18 references indexed in Scilit:
- Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant qualityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Permanent seed implantation for localized adenocarcinoma of the prostateCurrent Urology Reports, 2002
- 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcomeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinomaCancer, 1998
- A Dose–Response Study for I-125 Prostate ImplantsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic CarcinomaJournal of Urology, 1995
- Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiationCancer, 1995
- A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three‐dimensional dosimetryRadiation Oncology Investigations, 1995